215 related articles for article (PubMed ID: 32777068)
1. An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms.
von Drygalski A; Bhat V; Gale AJ; Averell PM; Cramer TJ; Elias DJ; Griffin JH; Mosnier LO
Blood Adv; 2020 Aug; 4(15):3716-3727. PubMed ID: 32777068
[TBL] [Abstract][Full Text] [Related]
2. An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C.
von Drygalski A; Bhat V; Gale AJ; Burnier L; Cramer TJ; Griffin JH; Mosnier LO
PLoS One; 2014; 9(8):e104304. PubMed ID: 25127130
[TBL] [Abstract][Full Text] [Related]
3. An engineered activated factor V for the prevention and treatment of acute traumatic coagulopathy and bleeding in mice.
Joseph BC; Miyazawa BY; Esmon CT; Cohen MJ; von Drygalski A; Mosnier LO
Blood Adv; 2022 Feb; 6(3):959-969. PubMed ID: 34861695
[TBL] [Abstract][Full Text] [Related]
4. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents.
Kaide CG; Gulseth MP
J Emerg Med; 2020 Feb; 58(2):217-233. PubMed ID: 31831187
[TBL] [Abstract][Full Text] [Related]
5. The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Buijs JT; Laghmani EH; van den Akker RFP; Tieken C; Vletter EM; van der Molen KM; Crooijmans JJ; Kroone C; Le Dévédec SE; van der Pluijm G; Versteeg HH
J Thromb Haemost; 2019 Jun; 17(6):951-963. PubMed ID: 30929299
[TBL] [Abstract][Full Text] [Related]
6. Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.
Bhat V; von Drygalski A; Gale AJ; Griffin JH; Mosnier LO
Thromb Haemost; 2016 Mar; 115(3):551-61. PubMed ID: 26466980
[TBL] [Abstract][Full Text] [Related]
7. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
Desai NR; Cornutt D
Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
[TBL] [Abstract][Full Text] [Related]
8. Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C.
Gale AJ; Xu X; Pellequer JL; Getzoff ED; Griffin JH
Protein Sci; 2002 Sep; 11(9):2091-101. PubMed ID: 12192065
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Direct Oral Anticoagulants on Antithrombin Activity Testing Is Abolished by DOAC-Stop in Venous Thromboembolism Patients.
Ząbczyk M; Natorska J; Kopytek M; Malinowski KP; Undas A
Arch Pathol Lab Med; 2021 Jan; 145(1):99-104. PubMed ID: 33367661
[TBL] [Abstract][Full Text] [Related]
11. Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal.
Karcioglu O; Zengin S; Ozkaya B; Ersan E; Yilmaz S; Afacan G; Abuska D; Hosseinzadeh M; Yeniocak S
Cardiovasc Hematol Agents Med Chem; 2022; 20(2):103-113. PubMed ID: 34521332
[TBL] [Abstract][Full Text] [Related]
12. Reversal of anticoagulants: an overview of current developments.
Greinacher A; Thiele T; Selleng K
Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
[TBL] [Abstract][Full Text] [Related]
13. Resolving DOAC interference on antithrombin activity testing on a FXa based method by the use of activated carbon.
Vercruyssen J; Meeus P; Bailleul E
Clin Chim Acta; 2023 Jan; 538():216-220. PubMed ID: 36574540
[TBL] [Abstract][Full Text] [Related]
14. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
Tummala R; Kavtaradze A; Gupta A; Ghosh RK
Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
Levy JH
Am J Med; 2016 Nov; 129(11S):S47-S53. PubMed ID: 27569675
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
[TBL] [Abstract][Full Text] [Related]
17. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?
Lippi G; Favaloro EJ
Clin Chem Lab Med; 2015 Feb; 53(2):185-97. PubMed ID: 25241734
[TBL] [Abstract][Full Text] [Related]
18. Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va.
Heeb MJ; Kojima Y; Hackeng TM; Griffin JH
Protein Sci; 1996 Sep; 5(9):1883-9. PubMed ID: 8880912
[TBL] [Abstract][Full Text] [Related]
19. How can we reverse bleeding in patients on direct oral anticoagulants?
Crowther M; Cuker A
Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
[TBL] [Abstract][Full Text] [Related]
20. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation.
Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ
Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
